66-23-08

Sp 1644

JUN 2 2005 %

Application No. (if known): 09/835,126

Attorney Docket No.: 20052/1200522-US1

Certificate of Express Mailing Under 37 CFR 1.10

	y certify that this correspondence is being deposit 20.441163	posited with the United States Postal Service as 667 – 05 in an envelope addressed to:
	MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	•
on	June 21, 2005 Date	
	:	
	Signature	ec/
	BY BY	
	Typed or printed name of perso	n signing Certificate
Regi	stration Number, if applicable	Telephone Number
Note:	Each paper must have its own certificate of reach submitted paper.	nailing, or this certificate must identify
	Amendment Transmittal (1 page) Amendment under 37 CFR 1.111 (13 Return Receipt Postcard	3 pages)

AMENI	DMENT T	[RANSM]	TTAL	FITER		cket No. 200522-US1			
Application		Filing Date		Examiner					
09/835,1	126	April 16,	2001 JUN 2	1 2005 6 Gambel		1644			
pplicant(s): Ran	·		PETER						
EX VIVO TREATMENT OF ALLOGENEIC AND GENEIC DONOR T-CELLS INVENTION: CONTAINING COMPOSITIONS (BONE MARROW) USING gp39 ANTAGONISTS AND USE THEREOF									
	TC	THE COMMI	SSIONER FO	OR PATENTS					
Fransmitted herev	with is an ame	ndment in the	above-identif	ied application.					
he fee has been	calculated and	d is transmitted	d as shown b	elow.					
			S AS AMEN	DED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate					
Total Claims	11	- 20 =		х					
Independent Claims	1	- 3 =		×					
Multiple Depend	ent Claims (ch	eck if applicabl	e)						
Other fee (please specify): TOTAL ADDITIONAL FEE FOR THIS AMENDMENT: Small Entitle						0.00			
Large Entity No additional fee is required for this amendment. Small Entity									
Please charge Deposit Account No in the amount of \$ A duplicate copy of this sheet is enclosed.									
A check in the amount of \$ to cover the filing fee is enclosed.									
Payment by	credit card. Fo	orm PTO-2038	is attached.						
The Director is hereby authorized to charge and credit Deposit Account No04-0100 as described below. A duplicate copy of this sheet is enclosed.									
x Credit any overpayment.									
Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.									
Lynn M. Ditch	Dital	1		Dated:	June 21	, 2005			
Attorney Reg. N	lo.: 54,071								
DARBY & DARI P.O. Box 5257 New York, New (212) 527-7665		257							

Docket No.: 20052/1200522-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 2 1 2005

In re Patent Application of: Randolph J. Noelle et al.

Application No.: 09/835,126

Filed: April 16, 2001

For: EX VIVO TREATMENT OF ALLOGENEIC

AND XENOGENEIC DONOR T-CELLS CONTAINING COMPOSITIONS (BONE MARROW) USING gp39 ANTAGONISTS

AND USE THEREOF

Conformation No.: 4674

Art Unit: 1644

Examiner: P. Gambel

AMENDMENT UNDER 37 C.F.R. § 1.111

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated March 24, 2005, rejecting claims 11-2, 4-11 and 13, please amend the above-identified U.S. patent application as follows and consider the following remarks.

Amendments to the Claims are reflected in the listing of claims that begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.